Abstract
Established in July 2012, Enroll-HD is both an integrated clinical research platform and a worldwide observational study designed to meet the clinical research requirements necessary to develop therapeutics for Huntington's disease (HD). The platform offers participants a low-burden entry into HD research, providing a large, well-characterized, research-engaged cohort with associated clinical data and biosamples that facilitates recruitment into interventional trials and other research studies. Additional studies that use Enroll-HD data and/or biosamples are built into the platform to further research on biomarkers and outcome measures. Enroll-HD is now operating worldwide in 21 countries at 159 clinical sites across four continents—Europe, North America, Latin America, and Australasia—and has recruited almost 25,000 participants, generating a large, rich clinical database with associated biosamples to expedite HD research; any researcher at a verifiable research organization can access the clinical datasets and biosamples from Enroll-HD and nested studies. Important operational features of Enroll-HD include a strong emphasis on standardization, data quality, and protecting participant identity, a single worldwide study protocol, a flexible EDC system capable of integrating multiple studies, a comprehensive monitoring infrastructure, an online portal to train and certify site personnel, and standardized study documents including informed consent forms and contractual agreements.
Author supplied keywords
Cite
CITATION STYLE
Sathe, S., Ware, J., Levey, J., Neacy, E., Blumenstein, R., Noble, S., … Sampaio, C. (2021, August 18). Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington’s Disease. Frontiers in Neurology. Frontiers Media S.A. https://doi.org/10.3389/fneur.2021.667420
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.